Nucleic Acid Therapeutics Market Report 2026

The nucleic acid therapeutics market size has grown rapidly in recent years. It will grow from $6.94 billion in 2025 to $8.01 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to limited availability of nucleic acid therapeutics, reliance on traditional small molecule therapies, growing demand for precision medicine, regulatory approvals for early gene therapies, increasing academic research on gene modulation.

The nucleic acid therapeutics market size is expected to see rapid growth in the next few years. It will grow to $14.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of crispr and other gene editing technologies, expansion of lipid nanoparticle (lnp) delivery systems, rising adoption of personalized nucleic acid therapies, increasing collaborations between pharma and biotech, growing investment in rna-based therapeutics. Major trends in the forecast period include rising adoption of antisense oligonucleotides (asos) and sirna therapies, expansion of crispr-based and gene editing therapeutics, growth in targeted therapies for neuromuscular, metabolic, and oncological disorders, increasing investment in non-viral and viral delivery systems, emergence of long non-coding rna (lncrna) and microrna (mirna) therapeutics.

The mounting prevalence of genetic and chronic diseases is poised to drive the nucleic acid therapeutics market forward. Genetic and chronic diseases encompass the interplay between hereditary genetic elements and the onset, advancement, or susceptibility to enduring ailments like diabetes, heart conditions, cancer, and autoimmune issues. This escalation mainly results from enhanced diagnostic tools that detect these disorders more precisely and promptly. Nucleic acid therapeutics prove valuable for genetic and chronic diseases by addressing root genetic drivers - through gene regulation, correction, or suppression - delivering targeted, individualized care. For instance, in October 2024, the Cystic Fibrosis Trust, a UK charity aiding cystic fibrosis patients, reported 11,148 registered cases in 2022, rising to 11,318 in 2023 - a 1.5% year-on-year jump in registrations. Thus, the growing burden of genetic and chronic diseases is spurring the nucleic acid therapeutics market.

Prominent firms in the nucleic acid therapeutics market are advancing novel solutions like antisense oligonucleotide therapy to pinpoint and mute disease-linked genes, providing exact treatments for genetic and rare conditions. Antisense oligonucleotide therapy employs brief, lab-made DNA or RNA strands to inhibit or alter expression of disease-related genes. For example, in December 2024, Ionis Pharmaceuticals Inc., a US biotech company, secured FDA approval for TRYNGOLZ (olezarsen) as a dietary adjunct to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare genetic condition marked by extreme hypertriglyceridemia (sHTG) and elevated acute pancreatitis (AP) risk. It marks the inaugural FDA-endorsed option for substantial, lasting triglyceride drops in this group, plus notable AP reductions paired with a low-fat diet. The treatment supports easy monthly self-injection via auto-injector.

In June 2025, Novartis AG, a Switzerland-based innovator in drug development and production, acquired Regulus Therapeutics Inc. for an undisclosed sum. This deal seeks to fortify Novartis's RNA-targeted drug expertise, enrich its portfolio for rare and chronic diseases, and hasten next-gen therapies leveraging Regulus's microRNA prowess. Regulus Therapeutics Inc. is a US biotech firm dedicated to microRNA-based therapies.

Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc.

North America was the largest region in the nucleic acid therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nucleic acid therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the nucleic acid therapeutics market by increasing the cost of imported raw materials, viral vectors, lipid nanoparticles, and advanced synthesis reagents. Segments such as gene therapies and RNA-based therapeutics are most impacted, particularly in regions like North America and Europe, which rely heavily on imports from Asia-Pacific. While tariffs have increased operational costs and slowed supply chains, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective delivery systems.

The nucleic acid therapeutics market research report is one of a series of new reports that provides nucleic acid therapeutics market statistics, including nucleic acid therapeutics industry global market size, regional shares, competitors with a nucleic acid therapeutics market share, detailed nucleic acid therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid therapeutics industry. This nucleic acid therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nucleic acid therapeutics are a class of treatments that use nucleic acids, including deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or their synthetic analogues, to modulate gene expression or correct genetic mutations, enabling disease treatment at the molecular level. These therapies employ synthetic DNA or RNA strands to precisely target and regulate specific genetic sequences, offering solutions for diseases that are difficult to address with conventional drugs.

The main therapy types of nucleic acid therapeutics include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), gene therapies, aptamers, and others. Antisense oligonucleotides (ASOs) are short, synthetic nucleic acid strands that bind to specific messenger RNA (mRNA) molecules to block or modify the expression of target genes. Nucleic acid therapeutics are applied across multiple therapeutic areas, including neuromuscular disorders, metabolic disorders, cardiovascular diseases, ophthalmological disorders, and oncology. They are administered through various routes such as intravenous and subcutaneous injections and utilize different delivery methods, including viral vector-based and non-viral systems. Key end users of these therapies include pharmaceutical companies, biotechnology firms, and government and academic research institutions.

The nucleic acid therapeutics market consists of revenues earned by entities by providing services such as custom oligonucleotide synthesis, gene silencing and editing services, drug discovery and development support, messenger RNA (mRNA) and small interfering RNA (siRNA) design and optimization, and delivery system development. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid therapeutics market also includes sales of messenger RNA (mRNA) therapeutics, clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing tools (therapeutic use), aptamers, and Amondys 45 (casimersen). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.